Information only - not offered by ASR

Information only - no FDA-approved product

DSIP / Emideltide

No FDA-approved counterpart was identified. FDA states that it lacks sufficient safety information for compounded emideltide.

A transparent starting point

What to know about DSIP / Emideltide

This page is for information only. ASR does not offer or prescribe this peptide. It is not a treatment recommendation or an invitation to request it.

FDA and compounding status

No FDA-approved counterpart was identified. FDA states that it lacks sufficient safety information for compounded emideltide.

FDA approval applies to the exact approved product. Compounded drugs are not FDA-approved and are not ASR peptide offerings.

Evidence and limitations

Research quality, studied populations, dosing, formulation, and route can differ. Results cannot be guaranteed, and findings about one product or route should not be applied automatically to another.

Risks and monitoring

Potential side effects, contraindications, interactions, pregnancy and breastfeeding considerations, storage, dosing, and follow-up depend on the exact product and the patient's health history. A clinician reviews these topics before FDA-approved treatment.

Primary regulatory references Review FDA compounding safety-risk information → Read FDA compounding questions and answers →